By Chris Wack
PepGen Inc. shares were up 19%, to $6.17, after the company said it saw positive results from its completed trial of PGN-EDO51, its lead product candidate for the treatment of certain Duchenne Muscular Dystrophy patients.
The biotechnology company's Phase 1 HNV trial of PGN-EDO51 was a single ascending dose clinical trial evaluating the safety and tolerability of PGN-EDO51 in 32 healthy adult males. Oligonucleotide tissue concentration and exon skipping also were assessed.
The trial met its primary endpoint assessing the safety profile of PGN-EDO51 at pharmacologically relevant doses. PGN-EDO51 was generally well tolerated.
PepGen now plans to begin a Phase 2a multiple ascending dose clinical trial in DMD patients in the first half of 2023.
All participants completed the trial; there were no discontinuations. The majority of treatment-emergent adverse events were assessed as mild and resolved without any intervention. At 10 mg/kg, there were only Grade 1 adverse events.
The stock hit its 52-week low of $4.32 last Friday, and is down 48% in the last three months.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 28, 2022 10:00 ET (14:00 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。